Summary

Eligibility
for people ages 1-30 (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Jennifer Michlitsch, MD (ucsf)
Headshot of Jennifer Michlitsch
Jennifer Michlitsch

Description

Summary

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.

Official Title

NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)

Keywords

Neuroblastoma, Eflornithine, Difluoromethylornithine (DFMO)

Eligibility

Locations

  • UCSF Benioff Children's Hospital Oakland- accepting new patients
    Oakland California United States
  • Rady Children's Hospital accepting new patients
    San Diego California 92123 United States

Lead Scientist at University of California Health

  • Jennifer Michlitsch, MD (ucsf)
    Professor, Pediatrics, School of Medicine. Authored (or co-authored) 23 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Giselle Sholler
Links
Beat Childhood Cancer Consortium Website
ID
NCT02679144
Phase
Phase 2 Neuroblastoma Research Study
Study Type
Interventional
Participants
Expecting 441 study participants
Last Updated